About KINAXO Exit

Evotec expands its drug discovery platform with cutting-edge technologies Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs. Strengthening Evotec’s position as quality leader in drug discovery The acquisition of Kinaxo confirms Evotec’s leading position as fully integrated drug discovery and